Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

INTRODUCTION: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. METHODS: We performed a post hoc pooled efficacy and safety analysis that included HCV genotype 1–infected patients with compensated liver disease and CKD stag...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Kidney Int Rep
Glavni autori: Bernstein, David E., Tran, Albert, Martin, Paul, Kowdley, Kris V., Bourliere, Marc, Sulkowski, Mark S., Pockros, Paul J., Renjifo, Boris, Wang, Deli, Shuster, Diana L., Cohen, Daniel E., Jacobson, Ira M.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2018
Teme:
Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6365509/
https://ncbi.nlm.nih.gov/pubmed/30775621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2018.10.005
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items